Abstract:CONTEXT: The use of systemic estrogens for the treatment of menopausal symptoms has declined by approximately 80% following the initial publication of the Women's Health Initiative in 2002. Current attention focuses on vaginal estrogen as a local therapeutic means to achieve control of symptoms due to vulvovaginal atrophy without increasing plasma estradiol levels. A key issue is whether or not vaginally administered estrogens are absorbed and produce systemic effects.EVIDENCE ACQUISITION: Medline and PubMed were searched for relevant English-language articles using pertinent key words. The bibliographies of the pertinent articles were then read to identify further relevant articles.EVIDENCE SYNTHESIS: Several confounding factors influenced the data analysis including: (1) estradiol assay sensitivity and specificity; (2) acute versus chronic absorption; (3) delivery systems, doses, timing, and formulation; and (4) effect of atrophic versus mature vaginal mucosa on absorption. Each preparation was associated with acute estradiol absorption with peaks at approximately 8 h and return to baseline at 12 h. Low-dose vaginal estrogen, arbitrarily defined as the 7.5-μg vaginal ring and 10-μg tablet, increased plasma estradiol levels during chronic administration but not above the normal range of ≤ 20 pg/ml. Surprisingly, these increments were associated with systemic effects to lower plasma levels of low density lipoprotein cholesterol and bone resorption rates. Intermediate doses (i.e. 25 μg estradiol or 0.3 mg conjugated equine estrogen) resulted in plasma estradiol levels approaching or exceeding 20 pg/ml. The higher doses (50-2000 μg estradiol or 0.625-2.5 mg conjugated equine estrogen) resulted in premenopausal levels of estrogen.CONCLUSIONS: Low-dose vaginal estrogen appears to be an effective strategy for managing women whose symptoms result from vulvovaginal atrophy. These regimens limit but do not completely eliminate systemic absorption. Low-doses regimens should be preferred clinically to intermediate- or high-dose methods.

Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review

Vaginal ring delivery of hormone replacement therapy--a review

Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring

Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy

Safety and acceptability of intravaginal rings releasing estradiol and progesterone

Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels

Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy

Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets

A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery

Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations

Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet

The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review

Treatment of postmenopausal vulvovaginal atrophy with estriol: a scientific update for 2014–2018

Vaginal epithelial surface appearances in women using vaginal rings for contraception

Impact of vaginal estriol on serum hormone levels: a systematic review

Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis

Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women

[Vaginal contraception: new form of administration of hormonal contraception]

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study

Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy

Pharmacotherapy for the treatment of vaginal atrophy